

Resource Summary Report

Generated by SPARC SAWG on Aug 11, 2026

pan Cytokeratin antibody [AE1/AE3] - BSA and Azide free

RRID:AB_1640401

Type: Antibody

Proper Citation

Abcam Cat# ab80826, RRID:AB_1640401

Antibody Information

URL: http://antibodyregistry.org/AB_1640401

Proper Citation: Abcam Cat# ab80826, RRID:AB_1640401

Target Antigen: pan Cytokeratin antibody [AE1/AE3] - BSA and Azide free

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012:
Immunohistochemistry; Immunofluorescence; Immunocytochemistry;
Immunohistochemistry - fixed; ICC/IF, IHC-P

Antibody Name: pan Cytokeratin antibody [AE1/AE3] - BSA and Azide free

Description: This monoclonal targets pan Cytokeratin antibody [AE1/AE3] - BSA and Azide free

Target Organism: chicken, monkey, rat, cow, mouse, chickenbird, rabbit, bovine, human

Antibody ID: AB_1640401

Vendor: Abcam

Catalog Number: ab80826

Record Creation Time: 20250820T012903+0000

Record Last Update: 20250820T110303+0000

Ratings and Alerts

No rating or validation information has been found for pan Cytokeratin antibody [AE1/AE3] - BSA and Azide free.

No alerts have been found for pan Cytokeratin antibody [AE1/AE3] - BSA and Azide free.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Guo J, et al. (2026) VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment. Cancer immunology research, 14(5), 718.

Marceaux C, et al. (2026) TNF- α -mediated myeloid-instructed CD14+CD4+ T cells are associated with poor survival in lung adenocarcinoma. Cell reports. Medicine, 7(2), 102593.

Zhu B, et al. (2025) Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. Cancer cell, 43(6), 1125.

Mukund K, et al. (2025) Spatially distinct cellular and molecular landscapes define prognosis in triple-negative breast cancer. Cell reports, 45(1), 116752.

Ziblat A, et al. (2024) Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell reports, 43(5), 114141.

Yonemura A, et al. (2024) Mesothelial cells with mesenchymal features enhance peritoneal dissemination by forming a protumorigenic microenvironment. Cell reports, 43(1), 113613.